title: Leuprorelin: a leading role in advanced prostate cancer therapy.
abstract: Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.
authors.affiliation: Bristol Royal Infirmary, University of Bristol.
authors.forename: Raj
authors.initials: R
authors.lastname: Persad
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008863:Microspheres; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide